Evidence map›Paper›PMID 29500548›Full record

ArticlePharmaceutical research2018

CpG-PEG Conjugates and their Immune Modulating Effects after Systemic Administration.

Caixing Wu, Xiaofei Xiang, Yang Yue, Lin Li, Yesen Li, Chong Zhang, Yuhong Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Caixing WuZhejiang-California International NanoSystems Institute, Zhejiang University, Hangzhou, China.
Xiaofei XiangSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Yang YueSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Lin LiSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Yesen LiZhejiang-California International NanoSystems Institute, Zhejiang University, Hangzhou, China.
Chong ZhangSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Yuhong XuCollege of Pharmacy and Chemistry, Dali University, Dali, China. yhxu@sjtu.edu.cn.ORCID http://orcid.org/0000-0001-5302-6392
Shanghai Jiao Tong University · CNZhejiang University · CNDali University · CN

Funding

National Natural Science Foundation of China 81690262
6 · The paper itself

Abstract

purposeSynthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs were found to be able to target cells that express Toll-like receptor 9 to modulate innate and adaptive immune reactions. But their in vivo application in immunotherapy against cancer has not been successful. We attempted in this study to examine polyethylene-glycol (PEG) conjugated CpG ODNs and investigated their mechanism of immune modulation in anti-cancer therapy.

methodsCpG-PEG conjugates with different PEG lengths were synthesized. In vitro activity as well as in vivo pharmacokinetics and pharmacodynamics properties were evaluated.

resultsCpG-PEG20Ks were found to be able to persist longer in circulation and activate various downstream effector cells. After intravenous injection, they resulted in higher levels of IL-12p70 in the circulation and lower M-MDSC infiltrates in the tumor microenvironment. Such activities were different from those of CpG ODNs without PEGylation, suggesting different PK-PD profiles systemically and locally.

conclusionsOur data support the development of CpG-PEGs as a new therapeutic agent that can be systemically administered to modulate immune responses and the microenvironment in tumor tissues.

Indexed as

Adaptive ImmunityAnimalsCell Line, TumorCells, CulturedDendritic CellsDisease Models, AnimalDrug CompoundingDrug Evaluation, PreclinicalFemaleHumansInjections, IntravenousInterleukin-12MaleMiceMice, Inbred BALB CMice, Inbred C57BLCpG ODN 1826Interleukin-12OligodeoxyribonucleotidesOvalbuminPolyethylene GlycolsCpG-ODNimmune modulationPEGsystemic administation

Identifiers

PMID29500548
OpenAlexW2789819731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.